Methylphenidate Hydrochloride Laboratorios Rubio Sa

Methylphenidate Hydrochloride, the active ingredient in Methylphenidate Hydrochloride Laboratorios Rubio Sa, is a central nervous system stimulant presented as an oral formulation for oral use. It is indicated for the treatment of attention deficit hyperactivity disorder and narcolepsy in appropriate patient populations. The drug works by inhibiting the reuptake of dopamine and norepinephrine, thereby increasing their synaptic concentrations and improving focus while reducing excessive daytime sleepiness.

GNH USA supplies Methylphenidate Hydrochloride Laboratorios Rubio Sa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methylphenidate Hydrochloride is used in central nervous system stimulant therapy for specific neurobehavioral disorders.

- Attention Deficit Hyperactivity Disorder (ADHD): improves attention, reduces hyperactivity and impulsivity. - Narcolepsy: decreases excessive daytime sleepiness and cataplexy episodes. - Attention Deficit Disorder (ADD): enhances concentration and academic performance in individuals with attention deficits.

Methylphenidate Hydrochloride may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced food intake. - Headache: mild to moderate cranial pain. - Stomach pain: abdominal discomfort.

Serious or Rare Side Effects: - Cardiovascular events: chest pain, hypertension, or arrhythmia. - Psychosis: hallucinations or delusional thinking.

When prescribing Methylphenidate Hydrochloride, clinicians should observe several precautions to ensure patient safety.

- Assess cardiovascular status: evaluate blood pressure and heart rate before initiating therapy. - Monitor growth in children: track height and weight regularly during treatment. - Avoid use in severe anxiety: the stimulant may exacerbate anxiety symptoms. - Use caution with MAO inhibitors: concurrent use can precipitate hypertensive crisis. - Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture.

Methylphenidate Hydrochloride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis when combined. - Antihypertensive agents (e.g., alpha‑blockers): may reduce blood pressure control. - Tricyclic antidepressants: increased risk of cardiovascular side effects.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine): may raise methylphenidate plasma levels. - Antihistamines: can enhance sedation or reduce stimulant effect. - SSRIs: may increase risk of serotonin syndrome.